- Combining 6-month goserelin (androgen deprivation treatment; ADT) with salvage radiotherapy significantly improves 120-month PFS and metastasis-free survival (MFS) in patients with prostate cancer with biochemical relapse after radical prostatectomy vs salvage radiotherapy alone.
Why this matters
- Study supports the use of ADT with standard radiotherapy in these patients.
- 112-month follow-up analysis of phase 3 GETUG-AFU 16 study of 743 patients with prostate cancer with initial undetectable PSA increasing to 0.2-2 ng/mL after radical prostatectomy.
- Patients were randomly assigned to radiotherapy±goserelin.
- Funding: The French Health ministry; AstraZeneca; others.
- At data cutoff, median follow-up was 112 months.
- Radiotherapy+goserelin vs radiotherapy alone significantly improved:
- 120-month PFS (64% vs 49%; HR, 0.54; P<.0001>
- 120-month MFS (75% vs 69%; HR, 0.73; P=.0339).
- Open-label design.